Clinical response in patients with ovarian cancer treated with metronomic chemotherapy

Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, dos...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Perroud, Herman A, Scharovsky, O. Graciela, Rozados, Viviana R., Alasino, Carlos María
Formato:	article artículo publishedVersion
Lenguaje:	Inglés
Publicado:	Cancer Intelligence 2018
Materias:	ovarian cancer metronomic chemotherapy cyclophosphamide
Acceso en línea:	http://hdl.handle.net/2133/11512 http://hdl.handle.net/2133/11512
Aporte de:	Repositorio Hipermedial de la Universidad Nacional de Rosario (UNR) de Universidad Nacional de Rosario

Ejemplares similares

Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response
por: Perroud, Herman A, et al.
Publicado: (2018)

Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer
por: Perroud, Herman A, et al.
Publicado: (2018)

Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
por: Perroud, Herman A, et al.
Publicado: (2018)

The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide
por: Rozados, Viviana R., et al.
Publicado: (2012)

Comparative Effectiveness of Two Metronomic Chemotherapy Schedules. Our Experience in the Preclinical Field
por: Rico, María José, et al.
Publicado: (2018)

Metronomic chemotherapy: changing the paradigm that more is better
por: Scharovsky, O. Graciela, et al.
Publicado: (2012)

Achievements and challenges in the use of metronomics for the treatment of breast cancer
por: Scharovsky, O. Graciela, et al.
Publicado: (2020)

Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity
por: Rozados, Viviana R., et al.
Publicado: (2012)

Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas
por: Mainetti, Leandro Ernesto, et al.
Publicado: (2018)

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milan
por: Bouche, Gauthier, et al.
Publicado: (2018)

Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
por: Rico, María José, et al.
Publicado: (2018)

Sustainable chemotherapy schedules
por: Barrea, Andrés Alberto, et al.
Publicado: (2021)

Sustainable chemotherapy schedules
por: Barrea, Andrés Alberto, et al.
Publicado: (2021)

Cancer chemotherapy and biotherapy : principles and practice /
Publicado: (2006)

The chemotherapy source book /
Publicado: (2008)

Modulation of IL-10/IL-10R expression by mafosfamide, a derivative of 4-hydroxycyclophosphamide, in a rat B-cell lymphoma
por: Rico, María José, et al.
Publicado: (2013)

Neoadjuvant breast cancer: statistical and histopathological analysis of tumor response. Casuistry of the National Hospital of Clinics
por: Anglada , GA, et al.
Publicado: (2023)

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
por: Blajman, C., et al.

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
Publicado: (1999)

The understanding of information about oral chemotherapy treatment among outpatients at a University Hospital in Ceará, Brazil
por: Pereira, Ana G. da S., et al.
Publicado: (2010)

Clinical characteristics of patients with Breast and / or Ovarian Cancer with mutations in the BRCA1 and BRCA2 genes in Córdoba, Argentina
por: Martin, Claudia Alejandra, et al.
Publicado: (2022)

A Symmetrical Dirhenium(I) Complex with 4,4’’-Azobis(2,2’-bipyridine) as a Bridging Ligand: Synthesis, Physicochemical Properties and Applications in Detection of Biologically Relevant Thiols and in Chemotherapy for Bone Cancer
por: Abate, Pedro Oscar, et al.
Publicado: (2020)

Regulatory T cells but not NKT I cells are modulated by a single low-dose cyclophosphamide in a B cell lymphoma tumor-model
por: Rico, María José, et al.
Publicado: (2012)

Targeted therapy in translational cancer research /
Publicado: (2016)

Distribution of FMR1 and FMR2 repeats in Argentinean patients with primary ovarian insufficiency
por: Espeche, L.D., et al.

Distribution of FMR1 and FMR2 repeats in Argentinean patients with primary ovarian insufficiency
Publicado: (2017)

Manual de quimioterapia del cáncer /
Publicado: (2012)

Handbook of targeted cancer therapy /
Publicado: (2015)

Cognitive deficits with chemotherapy in women with breast cancer:: a bibliographic revisión
por: Arce, Bernardo, et al.
Publicado: (2023)

Inmunomodulación y antiangiogénesis en la terapéutica oncológica. De la investigación básica a la clínica
por: Scharovsky, O. Graciela, et al.
Publicado: (2012)

Pharmacotherapeutics for advanced practice : a practical approach /
Publicado: (2013)

A Novel Synergistic Combination of Cyclophosphamide and Gene Transfer of Interleukin-12 Eradicates Colorectal Carcinoma in Mice
por: Malvicini, Mariana, et al.
Publicado: (2012)

Pharmacogenetics of breast cancer : towards the individualization of therapy /
Publicado: (2008)

Polycystic ovarian syndrome: temporal characterization of the induction and reversion process in an experimental model
por: Salvetti, Natalia Raquel, et al.
Publicado: (2004)

Clinical and experimental hypertension

The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide
por: Zacarías Fluck, M.F., et al.

Essential cancer pharmacology : the prescriber's guide /
por: Butler, Sara K.
Publicado: (2011)

Melatonin reverses oxidative damage in the submandibular gland of rats treated with Cyclophosphamide
por: Bachmeier, Evelin, et al.
Publicado: (2023)

Interaction between IGF1 and IGFBPs in bovine cystic ovarian disease
por: Rodríguez, Fernanda Mariel, et al.
Publicado: (2013)

Effects of adrenalin on ovarian injury formed by ischemia reperfusion in rats
por: Yilmaz, Mehmet, et al.
Publicado: (2012)